Oncology News

LONDON--(BUSINESS WIRE)--A child was the first patient treated at Stanford Medicine using Leo Cancer Care's Marie® — world's first compact upright proton therapy....

NASHVILLE, Tenn.--(BUSINESS WIRE)--Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, today announced the commercial launch of Mosaic Reporting™, a new class of AI-native radiology reporting solution available as part of MosaicOS™. Mosaic Reporting is already deployed to thousands of radiologists through Radiology Partners-affiliated practices, giving Mosaic a scaled real-world environment to refine and expand the platform. Powered by foundation models developed by...

BOSTON--(BUSINESS WIRE)--Dana-Farber Cancer Institute today announced that the Yawkey Foundation made a generous $50 million grant to support Dana-Farber's planned cancer hospital and the Future of Cancer Care Fund. The gift commemorates an eight-decade partnership and will help support construction of Dana-Farber's future cancer hospital and other critical priorities including accelerating cancer research, and advancing early detection, survivorship, psychosocial services, and patient assistan...

LOS ANGELES--(BUSINESS WIRE)--The Prostate Cancer Foundation (PCF) today announced the start of the 31st season of its Home Run Challenge (HRC), a nationwide campaign that has raised $150 million since its inception by turning every Major League Baseball home run into support for lifesaving prostate cancer research, awareness and early detection. Founded by PCF Chairman Mike Milken, the Home Run Challenge was created to “Keep Dad in the Game,” inspiring generations of baseball fans across Ameri...

CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics Appoints Rich Ramko to Board of Directors...

MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company advancing molecularly targeted intraoperative imaging, today announced the appointment of Adam Gridley as President and Chief Executive Officer. Mr. Gridley succeeds John Santini, Ph.D., who will transition to the role of Chief Technology Officer, continuing to lead the company’s scientific innovation and long-term technology strategy. Mr. Gridley brings more than 30 years of commercial and late-stage clini...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI model for tumor and immune biology, today announced it has been named a Diamond winner in the 2026 Pinnacle Awards for Healthcare. Recognized in the Innovator in Biotech Solutions category, BostonGene was honored for its work in enabling better decision-making across drug development. The Pinnacle Awards celebrate global excellence and innovation, highlighting organizations that are advancing medical technology and redefin...

AUSTIN, Texas--(BUSINESS WIRE)--Zetagen Therapeutics, a clinical‑stage biopharmaceutical company developing novel therapies for primary and metastatic breast cancer, today announced preliminary topline results from its Phase 2a clinical study evaluating ZetaMet™ (Zeta BC 003) in subjects with metastatic breast cancer (MBC) with lytic bone lesions. In this open‑label study, no skeletal‑related events (SREs) or fractures were observed, no treatment‑emergent adverse events (AEs) or serious adverse...

MOUNTAIN VIEW, Calif. & GOLDEN, Colo. & HONG KONG--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a qualified acquisition corp and Ignite Proteomics, LLC (“Ignite”, or “Ignite Proteomics”), a functional proteomics company and 100%-owned subsidiary of Aditxt, today announced that Ignite and strategic counterparty agreed to sign a definitive business combination agreement. The transaction values Ignite at an implied equity value of approximately $150 million, subject to the terms and co...

MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm today announced the appointment of Peter Garcia as Chief Financial Officer (CFO). Mr. Garcia brings more than three decades of biotechnology and oncology financial leadership experience, with a proven track record of leading transformative financings, strategic transactions, and scaling finance organizations to support global clinical development and commercialization. “Pete joins CatalYm at an important stage of growth for our company, with mult...